Key result
The magnitude of blood pressure reduction, rather than the specific class of antihypertensive medication used, is the major determinant of reducing adverse cardiovascular events in patients with essential hypertension.
Why the study?
Most patients with hypertension do not receive treatment or remain undertreated, prompting new guidelines with conscientious strategies to achieve strict blood pressure goals.
What are the optimal pharmacotherapy strategies and medications for managing essential hypertension?
What are the optimal pharmacotherapy strategies and medications for managing essential hypertension?
This review summarizes current pharmacotherapy strategies for essential hypertension to help clinicians achieve stricter blood pressure goals recommended by new guidelines.
Answers are grounded in this paper and cite their sources.
Supports BP reduction magnitude focus over drug class in essential hypertension; leaves open optimal regimens for subgroups.
Hypertension is one of the leading causes of disability-adjusted life years and mortality, with approximately 15% prevalence worldwide. Most patients with hypertension from low- to high-income countries do not receive treatment. Among those who receive treatment, the majority remain undertreated and do not achieve their blood pressure goals. Therefore, new hypertension guidelines introduce more conscientious treatment strategies to maximize the probability of achieving the new strict blood pressure goals compared with the previous guidelines. Who should receive treatment for hypertension? Which antihypertensive medications have the strongest supporting data? Are generic and more affordable medications as effective as expensive brand medications? What are the different treatment strategies to maximize success in controlling blood pressure? Here, we briefly review pharmacotherapy for hypertension and provide answers to these questions as well as some other common questions regarding treatment of hypertension.
No takes yet. Share an insight, caveat, or question.
Heidari et al. (2022) conducted a review in Essential hypertension. Antihypertensive pharmacotherapy was evaluated. The magnitude of blood pressure reduction, rather than the specific class of antihypertensive medication used, is the major determinant of reducing adverse cardiovascular events in patients with essential hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: